Dianthus Therapeutics vs Spyre Therapeutics
DNTH and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and SYRE compare
Spyre Therapeutics is the larger company, worth 1.8 times as much as Dianthus Therapeutics ($8.5B against $4.6B).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | SYRE |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $8.5B |
| Share price | $82.38 | $96.56 |
| Change, 1 year | 144% | 305% |
| Change, 5 years | −34.5% | −47.2% |
| Beta (5Y) | 1.47 | 1.47 |
| Employees | 92 | 102 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.9× (better) | 7.7× |
| Profitability | ||
| Return on equity | −26.1% | −23.0% (better) |
| Return on invested capital | −25.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.10 (better) | 18.53 |
| Altman Z-score | 66.80 | 70.18 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 118% | 109% |
| Held by insiders | 9.1% | 20.4% |
| Insider net buying, 12 months | −$71.2M (better) | −$437M |
| Short interest, % of float | 18.0% | 18.3% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- SYRE stock overview
- SYRE income statement
- SYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.